Targeting liver and metabolic disorders

Israeli biotech 89Bio has just raised $60 million to advance its pipeline of biologic and small molecule treatments for liver and metabolic disorders. 89Bio’s BIO89-100 is in a phase 1 clinical trial for treating nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease.,7340,L-3748585,00.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *